{"_id": "65013913fddc0bb1312fb02c", "and": [{"$or": [{"cancer type": "breast cancer"}, {"cancer type": "gastric adenocarcinoma"}, {"cancer type": "gastroesophageal junction adenocarcinoma"}, {"cancer type": "colorectal cancer"}]}, {"$or": [{"HER2 amplification/overexpression": true}, {"uterine serous carcinoma": true}, {"HER2-mutated gastric or gastroesophageal junction adenocarcinoma without HER2-overexpression/amplification": true}]}, {"$and": [{"treatment history": {"$ne": "HER2-directed therapy"}}, {"treatment history": {"$ne": "trastuzumab"}}, {"treatment history": {"$ne": "doxorubicin-equivalent anthracyclines"}}, {"treatment history": {"$ne": "epirubicin-equivalent anthracyclines"}}, {"treatment history": {"$ne": "systemic anti-cancer therapy"}}, {"treatment history": {"$ne": "radiation therapy"}}, {"treatment history": {"$ne": "major surgery"}}, {"treatment history": {"$ne": "experimental agent"}}, {"clinical trial participation": {"$ne": true}}]}, {"performance status": {"$in": ["0", "1"]}}], "nctId": "NCT04579380", "title": "A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations"}